NK cells are essential for effective BCG immunotherapy
Open Access
- 30 April 2001
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 92 (5) , 697-702
- https://doi.org/10.1002/1097-0215(20010601)92:5<697::aid-ijc1245>3.0.co;2-z
Abstract
Adjuvant intravesical bacillus Calmette‐Guérin (BCG) therapy is a well‐established and successful adjuvant immunotherapy in the treatment of superficial bladder cancer. Although the function of natural killer (NK) cells in other immunotherapeutic regimens (e.g., lymphokine‐activated killer [LAK] cell or interleukin‐2 [IL‐2] therapy) has been established, the contribution of NK cells to effective BCG immunotherapy is not clear. We used a human in vitro system to analyze the role of NK cells in BCG‐induced cellular cytotoxicity. After stimulation of mononuclear cells with BCG for 7 days, these BCG‐activated killer (BAK) cells displayed substantial cytotoxicity against bladder tumor cells. Magnetic depletion experiments and fluorescence activated cell sorting revealed that NK cells were the major effector cell population. To address NK cell function in vivo, we studied a syngeneic orthotopic murine bladder cancer model and compared BCG immunotherapy in C57BL/6 wild‐type mice, NK‐deficient beige mice and mice treated with anti‐NK1.1 monoclonal antibody. Four weekly instillations of viable BCG significantly prolonged survival in wild‐type mice compared with control mice treated with solvent alone. In contrast, BCG therapy was completely ineffective in NK‐deficient beige mice and in mice treated with anti‐NK1.1 monoclonal antibody. These findings suggest a key role for NK cells during BCG immunotherapy.Keywords
This publication has 21 references indexed in Scilit:
- EFFECTS OF ACETYLIC SALICYLIC ACID AND PENTOXIFYLLINE ON THE EFFICACY OF INTRAVESICAL BCG THERAPY IN ORTHOTOPIC MURINE BLADDER CANCER (MB49)Journal of Urology, 1999
- Localization of IL-1, IL-2, IL-4, IL-8 and TNF in Superficial Bladder Tumors Treated with Intravesical Bacillus Calmette-GuerinJournal of Urology, 1996
- Mouse NK1.1+ T cells: a new family of T cellsImmunology Today, 1996
- The role of natural killer cells in immune surveillance of cancerCurrent Opinion in Immunology, 1995
- Tumor Antigens Recognized by T LymphocytesAnnual Review of Immunology, 1994
- IN VITRO ENHANCEMENT OF NATURAL KILLER CELL ACTIVITY BY BCG AND THE ANTAGONISTIC INHIBITION OF THE SUSCEPTIBILITY OF K562 CELLS TO LYSIS BY PERIPHERAL BLOOD LYMPHOCYTES IN PATIENTS WITH URINARY BLADDER TUMORInternational Journal of Urology, 1994
- Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-GuérinCancer Immunology, Immunotherapy, 1991
- Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.Journal of Clinical Investigation, 1990
- Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: Lack of a role of natural killer cellsClinical Immunology and Immunopathology, 1986
- Identification of a cell-surface antigen selectively expressed on the natural killer cell.The Journal of Experimental Medicine, 1977